Physician profile
Eugene Karpus
NPI 1831239920
$9,924.99
in general payments reported to CMS, 2019-2025
20 companies · $883 in 2025
The $883 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,617 · 2020: $202 · 2021: $1,893 · 2022: $1,350 · 2023: $2,092 · 2024: $1,887 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,862.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,885.57 | 2019-2024 | Invega Sustenna, Invega Trinza, Invega |
| Otsuka America Pharmaceutical, INC. | $1,681.99 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,092.33 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $1,032.13 | 2019-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $818.25 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $716.18 | 2019-2021 | |
| Axsome Therapeutics, INC. | $581.64 | 2023-2025 | Auvelity |
| Acadia Pharmaceuticals INC | $526.69 | 2019-2024 | Nuplazid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $455.41 | 2021-2023 | |
| Tris Pharma INC | $335.70 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $271.21 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $125.00 | 2025 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $91.55 | 2019 | |
| Vanda Pharmaceuticals INC. | $80.10 | 2024 | Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $36.56 | 2021 | |
| Dexcom, INC. | $21.61 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $20.12 | 2023 | Rexulti |
| Sun Pharmaceutical Industries INC. | $15.71 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Karpus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.